{
    "nctId": "NCT03314805",
    "briefTitle": "PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy",
    "officialTitle": "PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Cancer-related Fatigue, Neutropenia, Malignant",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 67,
    "primaryOutcomeMeasure": "Change in chemotherapy-related fatigue by brief fatigue Inventory",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women who are able to provide informed consent\n* Age 20 years and older\n* Diagnosis of stage II to III breast cancer\n* Patients who had undergone surgery for breast cancer treatment.\n* Planning to receive anthracycline -based adjuvant chemotherapy\n* Have adequate bone marrow, liver, and renal function\n* ECOG \u22661\n* Willing and able to complete quality of life questionnaires.\n\nExclusion Criteria:\n\n* Pregnancy or lactating women.\n* Baseline BFI score \\>3.\n* History of chronic fatigue syndrome, uncontrolled active infection, active cardiac disease, poor controlled hypertension or diabetes mellitus, any serious medical condition, psychiatric illness, and regular steroid therapy as determined by investigators.\n* History of previous breast cancer or other malignancy within the past 3 years with the exception of adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer.\n* Known severe allergy to Astragalus membranaceus or its mayor extracts (polysaccharides).",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}